Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of G-CSF with Adjuvant TAC in Breast Cancer
NCT01571518Phase 4Unknown
- Sponsor
- Hyuk moon Kim
- Start
- Apr 2012
- Primary completion
- Oct 2013
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of filgrastim in neutropenia (2 arms), sponsored by Hyuk moon Kim. Primary endpoint: frequency of neutropenia at 21 days. Status: unknown.
02
Drugs
filgrastim
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT01571518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01571518.